Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 421

1.
2.

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.

Dean RM, Pohlman B, Sweetenham JW, Sobecks RM, Kalaycio ME, Smith SD, Copelan EA, Andresen S, Rybicki LA, Curtis J, Bolwell BJ.

Br J Haematol. 2010 Jan;148(2):226-34. doi: 10.1111/j.1365-2141.2009.07940.x. Epub 2009 Oct 11.

PMID:
19821828
3.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):468-76.

PMID:
12374451
4.

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.

Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):493-500.

PMID:
12374454
5.

Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.

Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP.

Biol Blood Marrow Transplant. 2004 Sep;10(9):614-23.

6.

Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.

Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.

Ann Hematol. 2002 Feb;81(2):96-102. Epub 2002 Jan 10.

PMID:
11907790
7.

Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.

Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1447-54. doi: 10.1016/j.bbmt.2009.07.014. Epub 2009 Sep 1.

8.

Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.

Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH.

Bone Marrow Transplant. 2007 Nov;40(10):919-24. Epub 2007 Sep 10.

PMID:
17846602
9.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.

Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.

Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11.

10.

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.

Escalón MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M, Byrnes JJ, Fernandez HF.

Bone Marrow Transplant. 2009 Jul;44(2):89-96. doi: 10.1038/bmt.2008.429. Epub 2009 Jan 26.

PMID:
19169287
11.

Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.

Damon L, Rugo H, Tolaney S, Navarro W, Martin T 3rd, Ries C, Case D, Ault K, Linker C.

Biol Blood Marrow Transplant. 2006 Mar;12(3):316-24.

13.
14.

Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.

Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP.

Biol Blood Marrow Transplant. 2000;6(5A):548-54.

PMID:
11071260
15.

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE.

Biol Blood Marrow Transplant. 2002;8(3):145-54.

PMID:
11939604
16.

Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH, Mahmud N, Hurter E, Beri R, Rondelli D.

Bone Marrow Transplant. 2008 Jun;41(11):935-40. doi: 10.1038/bmt.2008.13. Epub 2008 Feb 11.

PMID:
18264144
17.

Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.

Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J, Pichlmeier U, Hahn JR, Holler E.

Bone Marrow Transplant. 2005 Feb;35(3):233-41.

PMID:
15592494
18.

Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.

Matthews RH, Emami M, Connaghan DG, Holland HK, Morris LE.

Bone Marrow Transplant. 2007 Apr;39(7):397-400. Epub 2007 Feb 26.

PMID:
17322933
19.

Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.

Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ.

Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98.

20.

High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.

Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.

Bone Marrow Transplant. 1998 Feb;21(4):383-9.

Supplemental Content

Support Center